{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:42:15Z","timestamp":1794271335608,"version":"4.9.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Thymectomy is one of the main treatments for thymoma associated myasthenia gravis, but there is a risk of acute exacerbation of myasthenia gravis symptoms during the perioperative period of thymoma. Therefore, perioperative management is very important. We reported four cases of thymoma associated generalized myasthenia gravis who were treated with efgartigimod before and after the perioperative period. The myasthenic symptoms of the patients were quickly controlled before surgery, and the patients successfully completed the surgery without experiencing myasthenic crisis or respiratory failure after surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>Four patients diagnosed with thymoma associated generalized myasthenia gravis were all acetylcholine receptor(AChR) antibody-positive, with case 2 also positive for Titin and anti-RyR antibodies. Prior to surgery, all patients exhibited varying degrees of myasthenic symptoms, with case 2 experiencing a myasthenic crisis induced by glucocorticoid pulse therapy before the operation. Admitted to our multidisciplinary treatment group for myasthenia gravis, all four patients received 1 to 2 treatments with efgartigimod before thymoma surgery, which led to an improvement in myasthenia symptoms and a significant reduction in MG-ADL and QMG scores. All four patients underwent video-assisted thoracoscopic mediastinal tumor resection under general anesthesia, followed by the 3rd to 4th treatments with efgartigimod postoperatively, with no perioperative myasthenic crisis occurring in any of the patients. Apart from case 1, who developed a new pulmonary infection postoperatively and experienced a temporary fluctuation in myasthenia symptoms, the other three patients had no severe complications. Follow-up visits at one month and three months postoperatively showed that three of the patients achieved minimum symptom expression (MG-ADL score \u22641).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Efgartigimod provides new insights into the perioperative management of thymomas in patients with thymoma associated generalized myasthenia gravis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1627584","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:30:29Z","timestamp":1759383029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Liuli","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.29399\/npa.27315","article-title":"History of myasthenia gravis revisited","volume":"58","author":"Deymeer","year":"2020","journal-title":"Noro Psikiyatr Ars"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.03.004","article-title":"Thymoma, myasthenia gravis, and other paraneoplastic syndromes","volume":"22","author":"Tormoehlen","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia gravis and associated diseases","volume":"6","author":"Tanovska","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0188-4409(02)00405-8","article-title":"Thymectomy in myasthenia gravis: response, complications, and associated conditions","volume":"33","author":"Remes-Troche","year":"2002","journal-title":"Arch Med Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jss.2020.12.048","article-title":"Risk factors for postoperative myasthenic crisis after thymectomy in patients with myasthenia gravis","volume":"262","author":"Huang","year":"2021","journal-title":"J Surg Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13019-020-01320-x","article-title":"Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies","volume":"15","author":"Liu","year":"2020","journal-title":"J Cardiothorac Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7507\/1007-4848.202202043","article-title":"Chinese clinical expert consensus on surgical treatment of myasthenia gravis","volume":"29","author":"Tan","year":"2022","journal-title":"Chin J Clin Thorac Cardiovasc Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.363824","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regener Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/S1474-4422(21)00216-7","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2024.109241","article-title":"Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report","volume":"115","author":"Wang","year":"2024","journal-title":"Int J Surg Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.04.014","article-title":"Perioperative safety and efficacy of efgartigimod for thymoma-associated myasthenia gravis: A prospective, multicenter, phase II clinical trial","volume":"20","author":"Wang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e50692","DOI":"10.7759\/cureus.50692","article-title":"Exacerbation of thymoma-associated myasthenia gravis following efgartigimod treatment related to anti-acetylcholine receptor antibody overshoot: A report of two cases","volume":"15","author":"Kawama","year":"2023","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2020.10.006","article-title":"Video-assisted thoracoscopic surgery for myasthenia gravis with thymoma: A six-year single-center experience","volume":"44","author":"Nguyen","year":"2021","journal-title":"Asian J Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome","volume":"271","author":"Di Stefano","year":"2024","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","article-title":"Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review","volume":"46","author":"Xu","year":"2025","journal-title":"Neurol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00415-025-13088-y","article-title":"Successful treatment of morvan syndrome with efgartigimod: report of two cases","volume":"272","author":"Wang","year":"2025","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27341","article-title":"Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis","volume":"64","author":"Ching","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1627584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:30:31Z","timestamp":1759383031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1627584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1627584"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1627584","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1627584"}}